Evidence map›Paper›PMID 34324367›Full record

SynthesisJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

Harold J Burstein, Mark R Somerfield, Debra L Barton, Ali Dorris, Lesley J Fallowfield, Dharamvir Jain, Stephen R D Johnston, Larissa A Korde, Jennifer K Litton, Erin R Macrae and 4 more

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
200citing papers in PubMed, 16 pooled it
28.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

200 citing papers in PubMed, 16 syntheses or guidelines pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Overall Survival with Inavolisib inThe New England journal of medicine · 2025
    Trial
  19. Trial
  20. Trial

140 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 14 institutions in 2 countries.

Harold J BursteinDana Farber Cancer Institute, Boston, MA.
Mark R SomerfieldAmerican Society of Clinical Oncology, Alexandria, VA.ORCID 0000-0001-5372-0085
Debra L BartonUniversity of Michigan School of Nursing, Ann Arbor, MI.ORCID 0000-0001-6624-3476
Ali DorrisLobular Breast Cancer Research Advocate, San Francisco, CA.
Lesley J FallowfieldUniversity of Sussex, Brighton, United Kingdom.
Dharamvir JainHouston Methodist Hospital and Health Care, Houston, TX.
Stephen R D JohnstonRoyal Marsden NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-9072-2749
Larissa A KordeClinical Investigations Branch, CTEP, DCTD, National Cancer Institute, Bethesda, MD.
Jennifer K LittonUniversity of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8390-4985
Erin R MacraeColumbus Oncology Associates, Columbus, OH.
Lindsay L PetersonDivision of Medical Oncology, Washington University School of Medicine, Saint Louis, MO.ORCID 0000-0002-5012-7347
Praveen VikasUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA.ORCID 0000-0001-9193-9889
Rachel L YungUniversity of Washington, Seattle, WA.ORCID 0000-0001-9142-7656
Hope S RugoUniversity of California San Francisco Comprehensive Cancer Center, San Francisco, CA.ORCID 0000-0001-6710-4814
American Society of Clinical Oncology · USBreast Cancer Research Foundation · USColumbus Oncology and Hematology Associates · USDana-Farber Cancer Institute · USMethodist Hospital · USNational Cancer Institute · USRoyal Marsden NHS Foundation Trust · GBThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Iowa · USUniversity of Michigan · USUniversity of Sussex · GBUniversity of Washington · USWashington University in St. Louis · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeTo update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.

methodsAn Expert Panel conducted a systematic review to identify new, potentially practice-changing data.

resultsFifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations. RECOMMENDATIONS: Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative,

Indexed as

Antineoplastic AgentsAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMolecular Targeted TherapyPractice Guidelines as TopicPrognosisReceptors, EstrogenReceptors, ProgesteroneAntineoplastic AgentsAntineoplastic Agents, HormonalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID34324367
PMCPMC8659999
OpenAlexW3184794943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.